Regen Biopharma Inc. (RGBP)

Overview

Regen BioPharma, Inc. is a pioneering firm rooted in the development of innovative regenerative medical applications within the United States. Since its inception in 2012, the company has dedicated its research and development efforts to unlock the potential of small molecules that modulate NR2F6, a critical regulator in the immune system. This focus serves a dual purpose: enhancing immune cell activation for cancer treatments and suppressing immune response for autoimmune diseases. Based in La Mesa, California, Regen BioPharma is at the forefront of exploring novel therapeutic avenues, albeit in the nascent stages of product and therapy development.

Products and Services

Regen BioPharma, Inc. has been concentrating its resources on two primary areas of research and development, which have significant implications for the treatment of oncology and autoimmune diseases.

• Immune Cell Activation for Oncology

  At the heart of Regen BioPharma's oncology efforts is the identification and development of small molecules designed to inhibit or activate the nuclear receptor subfamily 2, group F, member 6 (NR2F6). This approach aims at boosting the body's immune response against cancer cells. Since immune cells play a crucial role in identifying and eliminating cancerous cells, activating these cells can potentially offer a novel and effective treatment strategy for various cancers. Regen BioPharma’s research in this domain is part of their broader commitment to advancing cancer therapy through immune system modulation.

• Immune Cell Suppression for Autoimmune Diseases

  The company's focus extends to modulating the immune system for autoimmune conditions. By targeting NR2F6 to suppress immune cell activity, Regen BioPharma endeavors to develop therapies that could alleviate the symptoms of autoimmune diseases, wherein the immune system mistakenly attacks the body's own cells. The premise here aligns with the need for treatments that can effectively reduce such immune responses without adversely affecting the body's overall immunity. This research aims to fill a critical gap in autoimmune disease management, by offering new, targeted options for patients.